Table 6.
Univariate Analyses of factors associated with Relapse-free Survival and Overall Survival in HER2 Positive breast cancer patients (n=64).
| Variables | Relapse-free Survival
|
Overall Survival
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| CD4 (>16) | 2.95 | 0.95 to 9.21 | 0.067 | 3.25 | 1.22 to 8.67 | 0.017 |
| CD8 (>13) | 0.09 | 0.01 to 0.67 | 0.001 | 0.28 | 0.09 to 0.87 | 0.016 |
| γδ T (>9) | 39.39 | 4.99 to 310.65 | 5.42E-07 | 35.79 | 4.51 to 283.87 | 1.28E-06 |
| FoxP3 (>12) | 6.67 | 1.79 to 24.70 | 0.001 | 9.10 | 2.60 to 31.81 | 4.29E-05 |
| ER status (Pos) | 4.02 | 0.52 to 31.17 | 0.106 | 3.24 | 0.73 to 14.28 | 0.073 |
| Stage (III vs I + II) | 13.77 | 4.06 to 46.67 | 1.85E-05 | 13.53 | 4.53 to 40.47 | 2.05E-06 |
| Nodal (Pos) | NA | NA | 6.85E-08 | 14.84 | 3.36 to 65.43 | 3.44E-06 |
| Size (>2.1) | 2.93 | 0.88 to 9.77 | 0.068 | 4.23 | 1.38 to 13.04 | 0.006 |
Note: Results obtained using the Cox proportional hazard regression model.
Abbreviations: HR, hazard ratio; ER, estrogen receptor; FoxP3, forkhead box protein P3.
NA: not analysis. All patients with negative nodal status were no recurrence and alive during the follow-up period, and the software cannot perform the analysis.